Atherosclerosis vaccine - AVANT Immunotherapeutics

Drug Profile

Atherosclerosis vaccine - AVANT Immunotherapeutics

Alternative Names: CETi-1; CETP vaccine - AVANT; Cholesteryl ester transfer protein vaccine - AVANT

Latest Information Update: 18 Jun 2007

Price : $50

At a glance

  • Originator AVANT Immunotherapeutics
  • Class Antihyperlipidaemics; Vaccines
  • Mechanism of Action Cholesterol ester transfer protein inhibitors; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Discontinued Atherosclerosis; Low HDL cholesterol

Most Recent Events

  • 03 May 2007 Discontinued - Phase-II for Low HDL cholesterol in USA (Injection)
  • 03 May 2007 Discontinued - Phase-II for Atherosclerosis in USA (Injection)
  • 03 May 2007 AVANT is seeking partnerships for its cardiovascular programmes (
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top